Running of Fermion Observables in Non-Supersymmetric SO(10) Models

We investigate the complete renormalization group running of fermion observables in two different realistic non-supersymmetric models based on the gauge group $\textrm{SO}(10)$ with intermediate symmetry breaking for both normal and inverted neutrino mass orderings. Contrary to results of previous works, we find that the model with the more minimal Yukawa sector of the Lagrangian fails to reproduce the measured values of observables at the electroweak scale, whereas the model with the more extended Yukawa sector can do so if the neutrino masses have normal ordering. The difficulty in finding acceptable fits to measured data is a result of the added complexity from the effect of an intermediate symmetry breaking as well as tension in the value of the leptonic mixing angle $\theta^\ell_{23}$.Comment: 15 pages, 3 figures, 4 tables. Final version published in JHE

Fits to Non-Supersymmetric SO(10) Models with Type I and II Seesaw Mechanisms Using Renormalization Group Evolution

We consider numerical fits to non-supersymmetric $\mathrm{SO}(10)$-based models in which neutrino mass is generated by the type-I or type-II seesaw mechanism or a combination of both. The fits are performed with a sophisticated top-down procedure, taking into account the renormalization group equations of the gauge and Yukawa couplings, integrating out relevant degrees of freedom at their corresponding mass scales, and using recent data for the Standard Model observables. We find acceptable fits for normal neutrino mass ordering only and with neutrino mass generated by either type-I seesaw only or a combination of types I and II seesaw in which type-I seesaw is dominant. Furthermore, we find predictions from the best fit regarding the small neutrino masses, the effective neutrinoless double beta decay mass, and the leptonic CP-violating phase. Finally, we show that the fits are rather insensitive to the chosen value of the unification scale.Comment: 22 pages, 3 figures, 3 tables. Final version published in JHE

Realizing unification in two different SO(10) models with one intermediate breaking scale

We derive the threshold corrections in $\mathrm{SO}(10)$ grand unified models with the intermediate symmetry being flipped $\mathrm{SU}(5)\times\mathrm{U}(1)$ or $\mathrm{SU}(3)\times\mathrm{SU}(2)\times\mathrm{U}(1)\times\mathrm{U}(1)$, with the masses of the scalar fields set by the survival hypothesis. These models do not achieve gauge coupling unification if the matching conditions do not take threshold corrections into account. We present results showing the required size of threshold corrections for any value of the intermediate and unification scales. In particular, our results demonstrate that both of these models are disfavored since they require large threshold corrections to allow for unification with a predicted proton lifetime above current experimental bounds.Comment: 6 pages, 5 figures. Final version published in Eur. Phys. J.

Midlife risk factor exposure and incidence of cardiac arrest depending on cardiac or non-cardiac origin

Objective: Little is known about midlife risk factors of future cardiac arrest. Our objective was to evaluate cardiovascular risk factors in midlife in relation to the risk of cardiac arrest (CA) of cardiac and non-cardiac origin later in life. Methods: We cross-matched individuals of the population based Malmö Diet and Cancer study (n = 30,447) with the local CA registry of the city of Malmö. Baseline exposures were related to incident CA. Results: During a mean follow-up of 17.6. ±. 4.6. years, 378 CA occurred, of whom 17.2% survived to discharge. Independent midlife risk factors for CA of cardiac origin included coronary artery disease (HR 2.84 (1.86-4.34) (p 30kg/m2) (HR 2.37 (1.51-3.71) (p <0.001)), smoking (HR 2.05 (1.33-3.15) (p <0.001)) and being on antihypertensive treatment (HR 2.25 (1.46-3.46) (p <0.001)). Conclusion: Apart from smoking, which increases the risk of CA in general, the midlife risk factor pattern differs between CA of cardiac and non-cardiac origin. Whereas CA of cardiac origin is predicted by history of cardiovascular disease, dyslipidemia and diabetes mellitus, the main risk factors for CA of non-cardiac origin are obesity and hypertension. In addition to control of classical cardiovascular risk factors for prevention of CA, our results suggest that prevention of midlife obesity may reduce the risk of CA of non-cardiac origin

A minimal non-supersymmetric SO(10) model with Peccei–Quinn symmetry

Publisher's version (útgefin grein)We present a minimal non-supersymmetric SO(10) GUT breaking directly to the Standard Model gauge group. Precise gauge coupling unification is achieved due to the presence of two color-octet scalars, one of which is accessible to LHC searches. Proton lifetime is predicted to be below 4.5 × 1034 years, which is within the projected five-year sensitivity of the proposed Hyper-Kamiokande experiment. We find that the Standard Model observables are reproduced to a reasonable accuracy in a numerical fit, which also predicts the unknown neutrino parameters. Finally, the two scalar representations stabilize the electroweak vacuum and the dark matter is comprised of axionsS.M.B. thanks the “Roland Gustafssons Stiftelse för teoretisk fysik” for partial financial support. T.O. acknowledges support by the Swedish Research Council (Vetenskapsrådet) through contract No. 2017-03934 and the KTH Royal Institute of Technology for a sabbatical period at the University of Iceland. M.P. thanks “Stiftelsen Olle Engkvist Byggmästare” for financial support through contract No. 2017/85 (179) as well as “Roland Gustafssons Stiftelse för teoretisk fysik”. Numerical computations were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at PDC Center for High Performance Computing (PDC-HPC) at KTH Royal Institute of Technology in Stockholm, Sweden under project numbers PDC-2018-49 and SNIC 2018/3-559.Peer Reviewe

Evaluation of a Novel Teleradiology Technology for Image-Based Distant Consultations: Applications in Neurosurgery.

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadIn emergency settings, fast access to medical imaging for diagnostic is pivotal for clinical decision making. Hence, a need has emerged for solutions that allow rapid access to images on small mobile devices (SMD) without local data storage. Our objective was to evaluate access times to full quality anonymized DICOM datasets, comparing standard access through an authorized hospital computer (AHC) to a zero-footprint teleradiology technology (ZTT) used on a personal computer (PC) or SMD using national and international networks at a regional neurosurgical center. Image datasets were sent to a senior neurosurgeon, outside the hospital network using either an AHC and a VPN connection or a ZTT (Image Over Globe (IOG)), on a PC or an SMD. Time to access DICOM images was measured using both solutions. The mean time using AHC and VPN was 250 ± 10 s (median 249 s (233-274)) while the same procedure using IOG took 50 ± 8 s (median 49 s (42-60)) on a PC and 47 ± 20 s (median 39 (33-88)) on a SMD. Similarly, an international consultation was performed requiring 23 ± 5 s (median 21 (16-33)) and 27 ± 1 s (median 27 (25-29)) for PC and SMD respectively. IOG is a secure, rapid and easy to use telemedicine technology facilitating efficient clinical decision making and remote consultations. Keywords: clinical decision-making; neurosurgery; remote consultation; telemedicine; teleradiology

Low Progesterone and Low Estradiol Levels Associate with Abdominal Aortic Aneurysms in Men

Context Male sex is a major risk factor for abdominal aortic aneurysms (AAA) but few studies have addressed associations between sex hormone levels and AAA.ObjectiveTo describe the associations between serum sex steroids and early, screening-detected AAA in men.MethodsWe validated a high-sensitivity liquid chromatography-tandem mass spectrometry assay for comprehensive serum sex hormone profiling. This assay was then employed in a case-control study including 147 men with AAA (infrarenal aorta ≥30 mm) and 251 AAA-free controls recruited at the general population-based ultrasound screening for AAA in 65-year-old Swedish men.Outcomes includedAssociations between dehydroepiandrosterone, progesterone, 17α-hydroxyprogesterone, androstenedione, estrone, testosterone, dihydrotestosterone, and estradiol and AAA presence.ResultsDehydroepiandrosterone, progesterone, 17α-hydroxyprogesterone, testosterone, and estradiol, but not the other hormones, were lower in men with AAA. In models with adjustments for known AAA risk factors and comorbidity, only progesterone (odds ratio per SD decrease 1.62 [95% CI 1.18-2.22]) and estradiol (1.40 [95% CI 1.04-1.87]) remained inversely associated with the presence of AAA. Progesterone and estradiol contributed with independent additive information for prediction of AAA presence; compared with men with high (above median) levels, men with low (below median) levels of both hormones had a 4-fold increased odds ratio for AAA (4.06 [95% CI 2.25-7.31]).​​​​​​​ConclusionMeasured by a high-performance sex steroid assay, progesterone and estradiol are inversely associated with AAA in men, independently of known risk factors. Future studies should explore whether progesterone and estradiol, which are important reproductive hormones in women, are protective in human AAA.</p

Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.

AIMS Iron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and improved quality of life when used to treat ID at discharge in patients hospitalized for acute HF with left ventricular ejection fraction <50% in the AFFIRM-AHF trial. We quantified the effect of FCM on burden of disease and the wider pharmacoeconomic implications in France, Germany, Poland, Spain and Sweden. METHODS AND RESULTS The per country eligible population was calculated, aligning with the 2021 European Society of Cardiology (ESC) HF guidelines and the AFFIRM-AHF trial. Changes in burden of disease with FCM versus standard of care (SoC) were represented by disability-adjusted life years (DALYs), hospitalization episodes and bed days, using AFFIRM-AHF data. A Markov model was adapted to each country to estimate cost-effectiveness and combined with epidemiology data to calculate the impact on healthcare budgets. Between 335 (Sweden) and 13 237 (Germany) DALYs were predicted to be avoided with FCM use annually. Fewer hospitalizations and shorter lengths of stay associated with FCM compared to SoC were projected to result in substantial annual savings in bed days, from 5215 in Sweden to 205 630 in Germany. In all countries, FCM was predicted to be dominant (cost saving with gains in quality-adjusted life years), resulting in net savings to healthcare budgets within 1 year. CONCLUSIONS This comprehensive evaluation of FCM therapy highlights the potential benefits that could be realized through implementation of the ESC HF guideline recommendations regarding ID treatment.This work was supported by CSL Vifor, who provided support for model development, data analysis and medical writing for this study.S

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Aims: Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. Methods and results: The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5-5.3, P = 0.018) for OSS and 2.8 (0.3-5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3-5.6, P = 0.028) for OSS and 2.9 (0.2-5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. Conclusion: In iron-deficient patients with HF and left ventricular ejection fraction ≤50% who had stabilized after an episode of acute HF, treatment with IV FCM, compared with placebo, results in clinically meaningful beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to Week 24

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure:a multicentre, double-blind, randomised, controlled trial

Background Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. Methods AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin Findings Between March 21, 2017, and July 30, 2019, 1525 patients were screened, of whom 1132 patients were randomly assigned to study groups. Study treatment was started in 1110 patients, and 1108 (558 in the carboxymaltose group and 550 in the placebo group) had at least one post-randomisation value. 293 primary events (57.2 per 100 patient-years) occurred in the ferric carboxymaltose group and 372 (72.5 per 100 patient-years) occurred in the placebo group (rate ratio [RR] 0.79, 95% CI 0.62-1.01, p=0.059). 370 total cardiovascular hospitalisations and cardiovascular deaths occurred in the ferric carboxymaltose group and 451 occurred in the placebo group (RR 0.80, 95% CI 0.64-1.00, p=0.050). There was no difference in cardiovascular death between the two groups (77 [14%] of 558 in the ferric carboxymaltose group vs 78 [14%] in the placebo group; hazard ratio [HR] 0.96, 95% CI 0.70-1.32, p=0.81). 217 total heart failure hospitalisations occurred in the ferric carboxymaltose group and 294 occurred in the placebo group (RR 0.74; 95% CI 0.58-0.94, p=0.013). The composite of first heart failure hospitalisation or cardiovascular death occurred in 181 (32%) patients in the ferric carboxymaltose group and 209 (38%) in the placebo group (HR 0.80, 95% CI 0.66-0.98, p=0.030). Fewer days were lost due to heart failure hospitalisations and cardiovascular death for patients assigned to ferric carboxymaltose compared with placebo (369 days per 100 patient-years vs 548 days per 100 patient-years; RR 0.67, 95% CI 0.47-0.97, p=0.035). Serious adverse events occurred in 250 (45%) of 559 patients in the ferric carboxymaltose group and 282 (51%) of 551 patients in the placebo group. Interpretation In patients with iron deficiency, a left ventricular ejection fraction of less than 50%, and who were stabilised after an episode of acute heart failure, treatment with ferric carboxymaltose was safe and reduced the risk of heart failure hospitalisations, with no apparent effect on the risk of cardiovascular death